Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort

References

• Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009;181:601–7.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–17.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005–12.
   PubMed Web of Science ®Google Scholar
• Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112:1254–63.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938–42.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: astraightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039–46.
   PubMed Web of Science ®Google Scholar
• Kent M, Vickers AJ. A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer. J Urol 2015;193:1938–42.
   PubMed Web of Science ®Google Scholar
• Bratt O, Berglund A, Adolfsson J, Johansson JE, Tornblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol 2010;44:384–90.
   PubMed Web of Science ®Google Scholar
• Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm county, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013;63:419–25.
   PubMed Web of Science ®Google Scholar
• The National Prostate Cancer Register (NPCR) in Sweden 2012: Regional Oncologic Center: Uppsala 2013; [cited 2016 May 10]. Available from http://npcr.se/wp-content/uploads/2013/04/20131121-NPCR-Rapport-2012-ENG.pdf.
   Google Scholar
• Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3:143–52.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol 2009;5:1555–84.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248–53.
   PubMedGoogle Scholar
• Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–35.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000;18:3240–6.
   PubMed Web of Science ®Google Scholar
• Lughezzani G, Budaus L, Isbarn H, Sun M, Perrotte P, Haese A, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010;57:562–8.
   PubMed Web of Science ®Google Scholar
• Isbarn H, Karakiewicz PI, Walz J, Ahyai SA, Steuber T, Haese A, et al. External validation of a preoperative nomogram for prediction of the risk of recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2010;77:788–92.
   PubMed Web of Science ®Google Scholar
• Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer. BJU Int 2011;108:51–6.
   PubMed Web of Science ®Google Scholar
• Moreira DM, Presti JC, Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital and Duke prostate center databases. Prostate Cancer Prostatic Dis 2010;13:87–93.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Ohori M, Paul L, Yu C, Kattan MW, Ohno Y, et al. External validation of preoperative nomograms predicting biochemical recurrence after radical prostatectomy. Jpn J Clin Oncol 2013;43:1255–60.
   PubMed Web of Science ®Google Scholar
• Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol 2012;30:584–9.
   PubMed Web of Science ®Google Scholar
• Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 2008;72:396–400.
   PubMed Web of Science ®Google Scholar
• May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007;178:1957–62.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006;107:2384–91.
   PubMed Web of Science ®Google Scholar
• Harnden P, Shelley MD, Naylor B, Coles B, Mason MD. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review. Eur Urol 2008;54:728–39.
   PubMed Web of Science ®Google Scholar
• Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456–77.
   PubMed Web of Science ®Google Scholar